Caplin Point Laboratories Limited (CAPLIPOINT.NS)
INR 1911.2
(0.19%)
INR 1911.2
(0.19%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.63 Billion INR | 25.96% |
| 2022 | 2.88 Billion INR | 26.8% |
| 2021 | 2.27 Billion INR | 26.99% |
| 2020 | 1.79 Billion INR | -24.86% |
| 2019 | 2.38 Billion INR | 536.22% |
| 2018 | 374.45 Million INR | 31.59% |
| 2017 | 284.55 Million INR | 27.63% |
| 2016 | 222.94 Million INR | 18.5% |
| 2015 | 188.14 Million INR | 37.7% |
| 2014 | 136.63 Million INR | 39.58% |
| 2013 | 97.89 Million INR | -6.09% |
| 2012 | 104.24 Million INR | 63.5% |
| 2011 | 63.76 Million INR | 15.95% |
| 2010 | 54.99 Million INR | 32.38% |
| 2009 | 41.53 Million INR | -45.48% |
| 2008 | 76.18 Million INR | 22.6% |
| 2007 | 62.14 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 3.63 Billion INR | 0.0% |
| 2023 Q2 | 3.36 Billion INR | 0.0% |
| 2023 FY | 3.63 Billion INR | 25.96% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 2.96 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 2.88 Billion INR | 0.0% |
| 2022 FY | 2.88 Billion INR | 26.8% |
| 2021 Q2 | 2.37 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 2.27 Billion INR | 0.0% |
| 2021 FY | 2.27 Billion INR | 26.99% |
| 2020 FY | 1.79 Billion INR | -24.86% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 1.79 Billion INR | 0.0% |
| 2020 Q4 | 1.79 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 1 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 2.38 Billion INR | 0.0% |
| 2019 FY | 2.38 Billion INR | 536.22% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 374.45 Million INR | 0.0% |
| 2018 FY | 374.45 Million INR | 31.59% |
| 2018 Q2 | 266.81 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q4 | 284.55 Million INR | 0.0% |
| 2017 FY | 284.55 Million INR | 27.63% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 244.48 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 222.94 Million INR | 18.5% |
| 2016 Q4 | 222.94 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 152.57 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 FY | 188.14 Million INR | 37.7% |
| 2015 Q1 | 136.63 Million INR | 0.0% |
| 2015 Q2 | 116.44 Million INR | -14.78% |
| 2015 Q3 | 116.44 Million INR | 0.0% |
| 2015 Q4 | 188.14 Million INR | 61.57% |
| 2014 Q4 | - INR | -100.0% |
| 2014 FY | 136.63 Million INR | 39.58% |
| 2014 Q1 | 97.89 Million INR | 0.0% |
| 2014 Q2 | - INR | -100.0% |
| 2014 Q3 | 113.76 Million INR | 0.0% |
| 2013 Q1 | 104.24 Million INR | 0.0% |
| 2013 Q4 | - INR | -100.0% |
| 2013 FY | 97.89 Million INR | -6.09% |
| 2013 Q3 | 104.45 Million INR | 0.0% |
| 2013 Q2 | - INR | -100.0% |
| 2012 Q3 | 79.52 Million INR | 0.0% |
| 2012 Q1 | 63.76 Million INR | 0.0% |
| 2012 FY | 104.24 Million INR | 63.5% |
| 2012 Q4 | - INR | -100.0% |
| 2011 FY | 63.76 Million INR | 15.95% |
| 2010 FY | 54.99 Million INR | 32.38% |
| 2009 FY | 41.53 Million INR | -45.48% |
| 2008 FY | 76.18 Million INR | 22.6% |
| 2007 FY | 62.14 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 346.75 Million INR | -946.957% |
| Aarti Drugs Limited | 4.85 Billion INR | 25.284% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 43.527% |
| Ajanta Pharma Limited | 8.28 Billion INR | 56.174% |
| Alembic Limited | 113.4 Million INR | -3101.411% |
| Alkem Laboratories Limited | 26.61 Billion INR | 86.358% |
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 77.911% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | -59.311% |
| Bal Pharma Limited | 878.11 Million INR | -313.432% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -14138.538% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | -206.499% |
| Brooks Laboratories Limited | 96.1 Million INR | -3677.417% |
| Bafna Pharmaceuticals Limited | 296.41 Million INR | -1124.757% |
| Divi's Laboratories Limited | 31.84 Billion INR | 88.598% |
| Eris Lifesciences Limited | 1.89 Billion INR | -92.052% |
| Granules India Limited | 13 Billion INR | 72.086% |
| Ind-Swift Limited | 640.91 Million INR | -466.44% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -2320.751% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 27.755% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 71.849% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -9003.31% |
| Medicamen Biotech Limited | 593.75 Million INR | -511.434% |
| Medico Remedies Limited | 163.37 Million INR | -2122.168% |
| Wockhardt Limited | 6.4 Billion INR | 43.275% |
| Orchid Pharma Limited | 2.64 Billion INR | -37.397% |
| RPG Life Sciences Limited | 1.01 Billion INR | -259.446% |
| Shilpa Medicare Limited | 3.44 Billion INR | -5.251% |
| Sigachi Industries Limited | 707.2 Million INR | -413.343% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | -0.929% |
| Unichem Laboratories Limited | 7.04 Billion INR | 48.481% |
| Vaishali Pharma Limited | 3.79 Million INR | -95512.326% |
| Wanbury Limited | 360.23 Million INR | -907.795% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 89.452% |
| FDC Limited | 3.88 Billion INR | 6.647% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -1155.99% |
| Bajaj HealthCare Limited | 1.44 Billion INR | -152.044% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 94.288% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 45.538% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -3371.509% |
| Laurus Labs Limited | 18.45 Billion INR | 80.327% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | -193.627% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 48.806% |
| Par Drugs and Chemicals Limited | 41.77 Million INR | -8591.405% |
| Hester Biosciences Limited | 755.81 Million INR | -380.332% |
| Ipca Laboratories Limited | 24.71 Billion INR | 85.31% |
| Venus Remedies Limited | 1.21 Billion INR | -198.332% |
| ZIM Laboratories Limited | 812.62 Million INR | -346.748% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 96.299% |
| Morepen Laboratories Limited | 2.48 Billion INR | -46.037% |
| Neuland Laboratories Limited | 3.5 Billion INR | -3.601% |
| Sequent Scientific Limited | 3.46 Billion INR | -4.855% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | -57.027% |
| Valiant Laboratories Limited | 100.15 Million INR | -3524.818% |
| Windlas Biotech Limited | 621.89 Million INR | -483.769% |
| Hikal Limited | 3.03 Billion INR | -19.531% |
| Innova Captab Limited | 1.44 Billion INR | -152.083% |
| Procter & Gamble Health Limited | 1.09 Billion INR | -232.728% |
| Themis Medicare Limited | 705.74 Million INR | -414.408% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 14.547% |
| Mankind Pharma Limited | 15.53 Billion INR | 76.63% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 85.554% |
| Sakar Healthcare Limited | 277.32 Million INR | -1209.087% |
| Albert David Limited | 436.12 Million INR | -732.43% |
| Lupin Limited | 49.53 Billion INR | 92.672% |
| Gufic Biosciences Limited | 2 Billion INR | -81.083% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 96.321% |
| Lincoln Pharmaceuticals Limited | 771.68 Million INR | -370.453% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -1622.079% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 84.07% |
| NATCO Pharma Limited | 7 Billion INR | 48.174% |
| Suven Life Sciences Limited | 7.08 Million INR | -51140.649% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -3605.851% |
| Strides Pharma Science Limited | 11.26 Billion INR | 67.765% |
| Indoco Remedies Limited | 3.53 Billion INR | -2.827% |
| Alpa Laboratories Limited | 136.65 Million INR | -2556.656% |
| Lasa Supergenerics Limited | 190.43 Million INR | -1806.382% |
| Sun Pharma Advanced Research Company Limited | 14.79 Million INR | -24442.996% |